By Erik Rush
COVID-19 exposed vulnerabilities that had been building quietly within global life sciences supply chains for decades.
As borders closed, factories suspended operations, transportation networks became constrained, and demand for certain medical products surged almost overnight, healthcare systems and manufacturers discovered just how dependent they had become on complex international networks of suppliers. Personal protective equipment became difficult to obtain. Critical raw materials were delayed. Manufacturing capacity could not always be shifted quickly enough to meet demand.
The pandemic also demonstrated that supply-chain resilience is about considerably more than logistics. It encompasses manufacturing capacity, regulatory agility, supplier visibility, quality assurance, inventory strategy, geopolitical exposure, and even public policy.
Years later, debate continues over how governments responded to COVID-19. Recent investigations and legal proceedings have renewed questions surrounding transparency, recordkeeping, oversight, research funding, and decision-making during the crisis. These matters remain politically contentious, and allegations should not be confused with established findings. But regardless of where one falls in those debates, there is a broader lesson for life sciences organizations: systems designed to function efficiently under normal conditions may prove dangerously fragile when normal conditions disappear.
For pharmaceutical, biotechnology, medical device, diagnostics, and other healthcare companies, the question is no longer whether another major disruption will occur.
It is whether their supply chains will be ready when it does.
COVID-19 Revealed the Cost of an Efficiency-First Supply Chain
For decades, globalization encouraged companies to optimize supply chains around efficiency. Manufacturers consolidated production, relied on specialized suppliers, reduced inventories, and sourced materials from locations capable of delivering them at the lowest cost.
Under predictable conditions, the model could work remarkably well.
A pandemic is anything but predictable.
COVID-19 simultaneously disrupted supply and demand. Manufacturers faced shortages of materials and labor while healthcare systems urgently needed greater quantities of specific products. International transportation slowed. Export restrictions emerged. Demand became extraordinarily difficult to forecast.
The US Food and Drug Administration (FDA) subsequently identified many of the vulnerabilities that can contribute to shortages, including dependence on foreign suppliers, reliance on single or limited suppliers, transportation disruptions, manufacturing and quality problems, increased demand, and geopolitical events.
The lesson is not that globalization failed. Global networks remain essential to life sciences innovation and manufacturing.
The lesson is that efficiency without redundancy creates vulnerability.
The Pandemic Ended. The Supply Chain Risks Didn’t.
If COVID-19 were the only major threat confronting supply chains, companies could simply update their pandemic preparedness plans and move forward.
Instead, the risk environment has become more complicated.
Life sciences companies now operate amid geopolitical conflicts, shifting trade relationships, tariffs, export restrictions, transportation disruptions, natural disasters, changing regulatory expectations, cybersecurity risks, and intense competition for specialized materials and manufacturing capacity.
Dependence on concentrated sources of active pharmaceutical ingredients (APIs) and key starting materials (KSMs) is particularly significant. HHS has reported that China and India account for more than 70% of APIs and KSMs imported into the United States.
That does not mean companies should simply abandon international suppliers. Attempting to recreate every component of a global pharmaceutical supply chain domestically could be prohibitively expensive and, in many cases, impractical.
The better objective is diversification.
Companies need to understand where their greatest dependencies exist and determine what would happen if a supplier, manufacturing facility, country, transportation corridor, or material suddenly became unavailable.
Resilience Begins With Knowing What’s Behind Your Suppliers
A company may have dozens or hundreds of direct suppliers and still lack visibility into the deeper tiers of its supply chain.
That becomes dangerous when multiple supposedly independent suppliers rely on the same upstream manufacturer.
Imagine a pharmaceutical company purchasing an essential ingredient from three vendors. On paper, the company appears diversified. But if all three vendors obtain a precursor from the same overseas producer, the organization still has a single point of failure.
Resilient organizations therefore need greater visibility beyond Tier 1 suppliers.
That means identifying critical APIs, KSMs, excipients, packaging components, device components, laboratory materials, and other inputs and determining where they ultimately originate.
Organizations can then ask more useful questions:
- Which materials come from a single geographic region?
- Which products depend on only one qualified manufacturing facility?
- How quickly could an alternate supplier be qualified?
- Which transportation routes represent potential bottlenecks?
- How much inventory is available if normal deliveries stop?
- Which products would have the greatest patient impact if supply were interrupted?
This type of mapping transforms supply-chain management from procurement into enterprise risk management.
Diversification Must Be Qualified Before a Crisis
Finding another supplier after a disruption occurs is not the same as having an alternate supplier.
In a highly regulated industry, switching vendors may require audits, testing, validation, documentation, change controls, regulatory submissions, or other quality and compliance activities.
Waiting until the primary supplier fails can therefore leave an organization with an alternative source it cannot immediately use.
A more resilient model establishes qualified alternatives in advance.
The FDA has specifically highlighted the value of manufacturing drugs in more than one facility and geographic region, noting that alternative facilities can provide agility when operations at one location are curtailed.
For particularly critical materials and products, organizations should consider dual- or multi-sourcing strategies and periodically verify that backup suppliers can actually provide the required capacity.
Redundancy has a cost. But so does discovering during an emergency that the backup plan exists only on paper.
Strategic Inventory Is Making a Comeback
Just-in-time inventory became popular for good reason. Holding large quantities of materials ties up capital, requires storage, and can create expiration and obsolescence risks.
COVID-19 demonstrated the other side of that equation.
When supply stops, an extremely lean inventory provides very little time to respond.
The answer is not necessarily to stockpile everything. Instead, organizations can adopt a risk-based approach to strategic inventory.
Materials that are difficult to replace, have long lead times, originate from unstable regions, or are essential to high-priority products may justify larger safety stocks than readily available commodities.
Inventory decisions can therefore be based not simply on historical consumption but on the consequences of disruption.
Governments are applying similar thinking at the national level. U.S. policy has increasingly focused on securing critical medicines and pharmaceutical ingredients, including efforts to strengthen reserves of APIs used in medicines considered important to national health and security.
Regulatory Agility Is Part of Supply-Chain Resilience
Supply-chain and regulatory teams can no longer afford to operate in separate worlds.
Suppose a manufacturer identifies an alternate API supplier after its primary source becomes unavailable. Procurement may have solved the sourcing problem, but quality and regulatory teams still need to determine whether the alternative can be used and what approvals, filings, testing, validation, or documentation may be required.
The speed of that process can determine whether production continues.
Organizations can prepare by incorporating regulatory considerations into continuity planning before disruptions occur. Alternate suppliers, facilities, manufacturing processes, and transportation arrangements should be evaluated not merely for operational feasibility but for their regulatory implications.
This is becoming increasingly important as governments themselves reconsider how pharmaceutical manufacturing should be structured. FDA initiatives have sought to facilitate domestic manufacturing, while federal strategies emphasize reducing vulnerabilities associated with concentrated foreign sourcing.
For life sciences leadership teams, regulatory intelligence should consequently be treated as a supply-chain capability—not simply a compliance function.
Technology Can Turn Visibility Into Foresight
Companies cannot manage risks they cannot see.
Modern supply-chain platforms increasingly provide organizations with real-time or near-real-time information about suppliers, inventory, transportation, manufacturing capacity, quality events, and demand.
The next step is moving from visibility toward prediction.
Advanced analytics can help organizations recognize patterns that might signal trouble: deteriorating supplier performance, unusually long lead times, inventory imbalances, transportation bottlenecks, quality trends, or sudden changes in regional risk.
Digital tools can also support scenario modeling.
What happens if a port closes for 30 days? If a critical supplier loses regulatory approval? If demand doubles? If an API becomes unavailable? If tariffs dramatically change the economics of sourcing from a particular country?
Running those scenarios before they happen gives leadership teams an opportunity to make deliberate decisions rather than emergency ones.
Reshoring Can Help—but It Isn’t a Complete Solution
COVID-19 renewed interest in domestic manufacturing, particularly for critical medicines and pharmaceutical ingredients. That movement continues.
Reshoring can shorten certain supply chains, reduce exposure to geopolitical disruptions, and provide governments and manufacturers with greater control over strategically important production.
But “domestic” should not automatically be equated with “resilient.”
A domestic facility can still experience equipment failures, natural disasters, cyberattacks, labor shortages, quality problems, or shortages of imported raw materials.
The more important principle is avoiding excessive concentration.
A truly resilient supply chain may combine domestic manufacturing with trusted international suppliers, geographically distributed production, strategic inventories, qualified alternatives, and sufficient visibility to recognize emerging problems early.
The objective is not independence from the global economy. It is the ability to continue operating when one part of that economy becomes inaccessible.
Supply-Chain Resilience Is Ultimately a Leadership Issue
Perhaps the most important post-pandemic shift is conceptual.
Supply-chain resilience can no longer be treated solely as the responsibility of procurement and operations. A disruption can affect revenue, clinical trials, regulatory compliance, product launches, patient access, corporate reputation, and business continuity simultaneously. Supply-chain decisions therefore require participation from executive leadership as well as manufacturing, quality, regulatory, finance, IT, clinical, and commercial teams.
Organizations should establish clear governance around critical supply-chain risks and regularly test their assumptions. A contingency plan written five years ago is not necessarily a contingency plan today. Suppliers change. Regulations change. Political relationships change. Manufacturing footprints change. Products become more complex. New vulnerabilities emerge.
Resilience is therefore not something an organization achieves once. It is a capability that must be continuously maintained.
The Next Crisis Will Be Different
One of the greatest mistakes organizations could make is preparing specifically for another COVID-19.
The next global supply-chain crisis may look nothing like it.
It could originate with a geopolitical conflict, cyberattack, natural disaster, trade dispute, transportation shutdown, regulatory action, manufacturing quality event, or an unexpected shortage of a critical raw material.
The precise trigger matters less than the underlying capability to respond.
COVID-19 demonstrated how quickly assumptions about supply, demand, transportation, manufacturing capacity, and government policy can collapse. The controversies that continue to surround the pandemic response also underscore another lesson: during a crisis, transparency, credible information, accountability, and trust become strategic assets.
For life sciences organizations, the goal should not be to predict the next disruption perfectly. That is impossible. The goal is to build a supply chain capable of absorbing disruption without losing its ability to deliver.
That means knowing where vulnerabilities exist, diversifying critical suppliers, qualifying alternatives in advance, maintaining appropriate strategic inventory, integrating regulatory planning, improving visibility, testing contingencies, and treating resilience as an enterprise-wide responsibility.
The companies that internalize those lessons will be better prepared not only for the next crisis, but for the increasingly unpredictable environment in which life sciences organizations now operate.
Erik Rush is the Founder and Managing Director of Rush Media and Communications. Since 2004, RMC has helped medical, healthcare, pharmaceutical, biopharma, medical device, bioscience, veterinary, and health & wellness companies transform complex science into clear, credible, high‑performing marketing assets. Contact us to discuss how strategic content can help your organization communicate its expertise in a rapidly changing life sciences environment.